Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2021

Pharma News, 2021

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study for Vixotrigine in Small Fiber Neuropathy
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study for Vixotrigine in Small Fiber Neuropathy
CAMBRIDGE, Mass.
FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
CHICAGO, Sept.
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
GENEVA, Switzerland– September 17, 2021 – ObsEva SA (NASDAQ.
FDA Approves Exkivity as First Oral Therapy for Lung Cancer Subset
FDA Approves Exkivity as First Oral Therapy for Lung Cancer Subset
The FDA’s approval of Exkivity marks the first approved oral therapy for this subgroup of patients with non-small cell lung cancer.
BridgeBio Gets FDA Fast-Track Designation for Limb-Girdle Muscular Dystrophy Type 2i Treatment
BridgeBio Gets FDA Fast-Track Designation for Limb-Girdle Muscular Dystrophy Type 2i Treatment
BridgeBio Pharma Inc.
Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
CAMBRIDGE, Mass.
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
London, UK; 15 September 2021 – Pulmocide Ltd.
Research identifies possible link between antibiotic use and breast cancer growth
Research identifies possible link between antibiotic use and breast cancer growth
In a new study funded by Breast Cancer Now, scientists have identified a possible link between antibiotic use and the speed of breast cancer growth in mice.
J&J on Pace for Another Vaccine Success, this Time for Ebola
J&J on Pace for Another Vaccine Success, this Time for Ebola
Johnson & Johnson (JNJ.
Pancreatic Cancer Research Ramps Up as Roche and NovoCure Announce Partnership
Pancreatic Cancer Research Ramps Up as Roche and NovoCure Announce Partnership
Pancreatic cancer has the lowest survival rate of the most common cancers, less than 10% of patients survive longer than five years, largely due to most cases being diagnosed at a late stage.
AbbVie and REGENXBIO Announce Eye Care Collaboration
AbbVie and REGENXBIO Announce Eye Care Collaboration
NORTH CHICAGO, Ill.
Senhwa doses first subject in trial of Pidnarulex for solid tumours
Senhwa doses first subject in trial of Pidnarulex for solid tumours
The trial will determine the tolerable dose of Pidnarulex in solid tumour patients with BRCA1/2, PALB2 and HR gene mutations.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand